Mark Dickson
Memorial Sloan Kettering Cancer Center · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark Dickson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:09 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04967521 · SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated LiposarcomaSarcoma Alliance for Research through Collaboration · active not recruiting · Advanced Dedifferentiated Liposarcoma · principal investigator
- Ph2NCT02846987 · Study of Abemaciclib in Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center · active not recruiting · Sarcoma, Dedifferentiated Liposarcoma · principal investigator
- Ph2NCT01653028 · Alisertib in Treating Patients With Advanced or Metastatic SarcomaNational Cancer Institute (NCI) · completed · Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma · principal investigator
- Ph2NCT01209598 · PD0332991 (Palbociclib) in Patients With Advanced or Metastatic LiposarcomaMemorial Sloan Kettering Cancer Center · completed · Sarcoma, Liposarcoma · principal investigator
- Ph1/Ph2NCT01196416 · Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic MelanomaNational Cancer Institute (NCI) · completed · Recurrent Melanoma, Stage IV Skin Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT01653028
- U10CA031946RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01653028
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2014 to 2026Named on NCT01196416
- U01CA069856RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01196416
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:09 UTC. The ranking covers the 200 most relevant of 51 PubMed records, and a shared surname and initials can bring in a namesake. All 51 on PubMed
- 355 citationsRCR 10.3
- Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.J Clin Oncol · 2013352 citationsRCR 9.1
- 279 citationsRCR 7.9
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).Br J Cancer · 2011229 citationsRCR 4.8
- 167 citationsRCR 6.1
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.Lancet Oncol · 2013149 citationsRCR 4.2
- 149 citationsRCR 8.2
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.J Clin Oncol · 2016141 citationsRCR 3.8
- A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.Clin Cancer Res · 2011133 citationsRCR 3.6
- A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.Eur J Cancer · 2017113 citationsRCR 3.5